全文获取类型
| 收费全文 | 565855篇 |
| 免费 | 29523篇 |
| 国内免费 | 643篇 |
专业分类
| 耳鼻咽喉 | 7148篇 |
| 儿科学 | 19171篇 |
| 妇产科学 | 13179篇 |
| 基础医学 | 96883篇 |
| 口腔科学 | 13290篇 |
| 临床医学 | 51157篇 |
| 内科学 | 101931篇 |
| 皮肤病学 | 12838篇 |
| 神经病学 | 36164篇 |
| 特种医学 | 20834篇 |
| 外国民族医学 | 53篇 |
| 外科学 | 83521篇 |
| 综合类 | 8757篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 122篇 |
| 预防医学 | 40341篇 |
| 眼科学 | 13268篇 |
| 药学 | 44965篇 |
| 2篇 | |
| 中国医学 | 1419篇 |
| 肿瘤学 | 30976篇 |
出版年
| 2021年 | 5405篇 |
| 2019年 | 4803篇 |
| 2018年 | 7011篇 |
| 2017年 | 5059篇 |
| 2016年 | 6103篇 |
| 2015年 | 6577篇 |
| 2014年 | 8923篇 |
| 2013年 | 12540篇 |
| 2012年 | 18437篇 |
| 2011年 | 20205篇 |
| 2010年 | 11640篇 |
| 2009年 | 10128篇 |
| 2008年 | 17535篇 |
| 2007年 | 19276篇 |
| 2006年 | 18635篇 |
| 2005年 | 17770篇 |
| 2004年 | 17286篇 |
| 2003年 | 16442篇 |
| 2002年 | 15764篇 |
| 2001年 | 23055篇 |
| 2000年 | 23526篇 |
| 1999年 | 19395篇 |
| 1998年 | 5456篇 |
| 1997年 | 4554篇 |
| 1996年 | 4586篇 |
| 1995年 | 4284篇 |
| 1992年 | 14689篇 |
| 1991年 | 16077篇 |
| 1990年 | 16234篇 |
| 1989年 | 15853篇 |
| 1988年 | 14529篇 |
| 1987年 | 14382篇 |
| 1986年 | 13344篇 |
| 1985年 | 12868篇 |
| 1984年 | 9530篇 |
| 1983年 | 8093篇 |
| 1982年 | 4239篇 |
| 1979年 | 9028篇 |
| 1978年 | 6442篇 |
| 1977年 | 5219篇 |
| 1976年 | 5551篇 |
| 1975年 | 6657篇 |
| 1974年 | 7462篇 |
| 1973年 | 7203篇 |
| 1972年 | 6631篇 |
| 1971年 | 6360篇 |
| 1970年 | 5935篇 |
| 1969年 | 5483篇 |
| 1968年 | 5201篇 |
| 1967年 | 4636篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
21.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献22.
K.A. Lee M.T.A. Sharabiani D. Tumino J. Wadsley V. Gill G. Gerrard R. Sindhu M.N. Gaze L. Moss K. Newbold 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):385-390
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献23.
Sarah J. Schrauben Haochang Shou Xiaoming Zhang Amanda Hyre Anderson Joseph V. Bonventre Jing Chen Steven Coca Susan L. Furth Jason H. Greenberg Orlando M. Gutierrez Joachim H. Ix James P. Lash Chirag R. Parikh Casey M. Rebholz Venkata Sabbisetti Mark J. Sarnak Michael G. Shlipak Sushrut S. Waikar Paul L. Kimmel Ramachandran S. Vasan Harold I. Feldman Jeffrey R. Schelling 《Journal of the American Society of Nephrology : JASN》2021,32(1):115
24.
25.
26.
27.
28.
29.
30.